

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 03/072113 A1(51) International Patent Classification⁷: **A61K 31/7048**,
31/277, 47/32(74) Agent: **FITZPATRICKS**; 4 West Regent Street, Glasgow
G2 1RS (GB).(21) International Application Number: **PCT/GB03/00645**(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 12 February 2003 (12.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0204712.4 28 February 2002 (28.02.2002) GB(71) Applicant (*for all designated States except US*): **NOR-
BROOK LABORATORIES LIMITED** [GB/GB]; Sta-
tion Works, Newry, County Down, Northern Ireland BT35
6JP (GB).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BLAKELY, William**
[GB/GB]; 79 Chapel Road, Killeavy, Newry, County
Down, Northern Ireland BT35 8JZ (GB). **CROMIE, Lil-
lian** [GB/GB]; 65 Old Warrenpoint Road, Newry, County
Down, Northern Ireland BT34 2PN (GB). **DUFFY, Sean**
[GB/GB]; 3 New Road, Silverbridge, Newry, County
Down, Northern Ireland BT34 9PG (GB).

Published:

- with international search report
- with amended claims and statement

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: LONG ACTING PARASITICIDAL COMPOSITION CONTAINING A SALICYLANILIDE COMPOUND, A POLY-
MERIC SPECIES AND AT LEAST ONE OTHER ANTI-PARASITIC COMPOUND

(57) Abstract: A composition prepared for treating animals suffering from parasites which parasites are known to be susceptible to at least one of the avermectins, milbemycins or salicylanilides, comprises for example ivermectin in an amount of from 0.1 to 10 % (w/v), a solvent selected from the group consisting of glycerol formal, propylene glycol, polyethylene glycol and combinations thereof, and a salicylanilide such as closantel in a required dosage amount for the animal to be treated, typically about 2.5 mg/kg live weight of the animal to be treated, a polymeric species selected from the group consisting of polyvinylpyrrolidone and polyoxypropylene/polyoxyethylene block copolymers, the said polymeric species improving the bioavailability of closantel to the extent that blood plasma levels of the said compound greater than about 20 ppm over period of treatment are achievable.

WO 03/072113 A1

LONG ACTING PARASITICIDAL COMPOSITION CONTAINING
A SALICYLANILIDE COMPOUND, A POLYMERIC SPECIES
AND AT LEAST ONE OTHER ANTI-PARASITIC COMPOUND

Field of the Invention.

This invention relates to parasitocidal compositions, especially combination products for veterinary use, based on for example an avermectin or milbemycin
5 together with another parasitocidal agent. Such combination products exhibit efficacy across a broader spectrum of parasites than is observed with the use of a single parasitocidal agent alone.

Background of the Invention

Warm-blooded animals are subject to attack by parasites, and man has long
10 sought to combat such parasites afflicting domestic companion animals, farmed livestock and exotic animals, to alleviate suffering and for commercial gain. The manner of attack by the parasites, and the identification of a sensitive stage in the life cycle of the parasite, may influence greatly the choice of combating agent. Thus percutaneous treatments using topically applied preparations such as lotions,
15 paints, creams, gels, dusting powders, "pour-ons" and dips are commonly suitable for ectoparasites, but combating endoparasites requires careful selection of the method of administration and the delivery system. Oral drenches, pastes, boluses, tablets, and granules for incorporating into feed mixes are known methods capable of being used by the animal husbandrymen, but other methods which are intended
20 to avoid use of the gastrointestinal route are typically administered by qualified practitioners. Such other methods include use of aerosols, and parenteral drug compositions which are selectively prepared as solution or suspension or micronised powder formulations intended for subcutaneous, intracutaneous, and intramuscular injection according to the intended delivery regime. These last
25 methods require special care in formulation to avoid irritation at the site of injection or possible adverse allergic or pyrogenic reactions.

Injectable formulations are typically prepared using aqueous or non-aqueous ("solvent") vehicles. The latter class may comprise physiologically tolerable alcohols, glycols, esters, a limited range of organic aromatic solvents,
30 and vegetable oils and extracts or modified forms thereof. In selecting vehicles, the skilled worker has to consider a number of issues including, solubility of the intended active ingredient(s), the affinity of the drug to certain vehicles, whether it

will affect any essential auxiliaries, pH, stability over time, viscosity, and naturally the risk of any toxic effect upon the animal to be treated. Therefore, formulation of a parasiticide is a complex task.

Traditional parasiticides include chemical agents such as the
5 benzimidazoles, and carbamates, and plant extracts such as the pyrethroids, which tend to be used to combat ectoparasites such as ticks and mites.

The avermectins are very potent antiparasitic agents which are useful against a broad spectrum of endoparasites and ectoparasites in mammals as well as having agricultural uses against various parasites found in and on crops and
10 soil. The basic avermectin compounds are isolated from the fermentation broth of the soil micro-organism *Streptomyces avermitilis* and these compounds are described in US patent US 4 310 519. Furthermore, derivatives of these basic avermectin compounds have been prepared by a variety of chemical means.

Some of the avermectin group of compounds contain a 22, 23-double bond
15 and others contain a disaccharide at the 13-position which consists of α -L-oleandrosyl- α -L-oleandrosyl group. One or both saccharide units can be removed forming a monosaccharide or an aglycone (where both saccharides are removed) as described in US patent US 4206205. The aglycone derivatives possess a hydroxy group at the 13 position which may be removed to form the 13-deoxy
20 compound as described in the patents US 4 171 314 and US 4 173 571. Acylation of hydroxy groups on the avermectin compounds and derivatives can be carried out as described in US 4 201 861.

The milbemycin series of compounds, disclosed in US 3 950 360, are structurally similar to the avermectin family in that they contain the sixteen
25 membered macrocyclic ring. However, they do not contain the disaccharide sub-unit and there are differences in the substituent groups.

Ivermectin, disclosed in US 4 199 569, is prepared by the selective reduction of the 22, 23 double bond of the avermectin compounds. Ivermectin is a mixture of 22, 23-dihydro Avermectin B1a and B1b in a ratio of at least 80:20.

30 Ivermectin is an especially preferred active component in pesticidal compositions, and there is extensive literature on its activity, demonstrating its

efficacy against internal and external parasites, and its ability to interfere in the life cycle of certain parasites. The Merck Index (1996) cites several references including J.C.Chabala *et al*, J.Med.Chem.**23**, 1134 (1980); J.R.Egerton *et al*, Brit.Vet.J.**136**, 88 (1980); W.C.Campbell *et al*, Science **221**, 823-828 (1983) to mention but a few.

Formulation of ivermectin for the purposes of delivery in a variety of presentations, e.g. as an oral drench, pour-on, parenteral formulations, granules for adding to feed, and syringeable pastes. has proved highly challenging and numerous patents have been published on its use. Ivermectin exhibits a lipophilic character but it can be solvated in aqueous systems, and various patents describe special solvent systems for use in its formulation. Thus reference may be made at least to EP 0 045 655, and EP 0 146 414 for example.

Although ivermectin is surprisingly effective, and has enjoyed a long period of commercial success, there remains a keen interest in exploiting ivermectin against a wider range of parasites and in overcoming tolerance by some parasites which demands higher amounts of ivermectin to be delivered. Taking into account the fact that a significant volume of use of ivermectin is in protecting and treating animals intended for human consumption, there are constraints on the residual amount of ivermectin in the carcass of such an animal. Therefore, high loadings of ivermectin, even if technically feasible, in a delivery system are not necessarily the optimum solution.

Combination formulations are also desirable taking account of acquired tolerance or resistance in pests to prolonged usage of other more traditional parasitocidal agents. This phenomenon is well documented, e.g. in relation to worming compositions. Synergistic effects or complementary effects of combined parasitocidal agents have been observed as a route to combating the aforesaid tolerance problem. Synergistic anthelmintic compositions are discussed in WO 94/28887, which focuses on substituted mono- and bisphenols, salicylanilides, benzene sulphonamides, halogenated benzimidazoles, benzimidazoles, and benzimidazole carbamates.

The salicylanilides, tend to be effective against fungal attack, but the chemically modified derivative closantel is an effective worming agent. Closantel is described in US 4 005 218 and in the literature, e.g. J.Guerrero *et al*, J.Parasitol.68,616, (1983); H.Van den Bossche *et al*, Arch.Int.Physiol.Biochim, 87, 851(1979); H.J.Kane *et al*, Mol.Biochem.Parasitol.1, 347(1980).

The opportunity to combine the use of avermectins with other parasiticial agents has been explored already. Thus one finds that skin-absorbable pour-on formulations containing triclabendazole, optionally containing an avermectin, tetramisole or levamisole have been proposed in WO 0061068. An injectable formulation containing closantel together with an avermectin or milbemycin has been proposed in WO 95/05812. Formulations of the pour-on and injectable type are discussed in WO 01/60380, which comprise use of a pyrrolidone solvent and a bridging solvent such as a xylene, optionally including a further solubility agent such as propylene glycol caprylic acids and esters or peanut oil. This special solvent system is needed to address the difficulties of formulating differing parasiticial agents such as closantel and ivermectin together.

Salicylanilide derivatives such as closantel provide useful control over a range of parasites and are especially useful against liver fluke. The avermectin group of anti-parasitic compounds of which ivermectin is the best known example, provide complementary protection against many other parasites such as roundworms. Therefore, there are advantages to be gained if a combination of these drugs could be provided in a form that can be conveniently administered to livestock and which will provide effective control of parasitic infection.

For ivermectin and closantel the established dose rate for injection of livestock is of the order of 200 µg/kg (ivermectin) and 2.5mg/kg (closantel). Provision of a satisfactory aqueous formulation is problematical because the optimum pH for each drug is different. An acidic system providing the optimum pH for ivermectin, whereas closantel requires an alkaline medium for satisfactory dissolution.

Accordingly non-aqueous or essentially non-aqueous formulations were investigated. Ivermectin can be prepared in non-aqueous or low water content

systems that are suitable for injection. Glycerol formal, propylene glycol, polyethylene glycol, pyrrolidone, and related solvents have been used in various formulations, singly or in combination. Patent publication WO 95/05812 discloses closantel and ivermectin solutions for injection using some of the solvents established as suitable for ivermectin (glycerol formal, polyethylene glycol, propylene glycol and water). However the effectiveness of the formulations, in terms of bioavailability of the active parasitocidal agents, described in that patent application were not disclosed.

The results of our research into the efficacy of such formulations are summarised in Table 1 presented hereinbelow.

In order to evaluate formulations of the type described in the reference WO 95/05812, administration of an ivermectin/closantel combination product as disclosed therein, at a dosage corresponding to 2.5 mg/kg closantel was carried out according to established industry practices. However, this failed to produce blood plasma levels of closantel greater than 20 ppm (Examples 1 and 2 in Table 1 reported hereinafter). According to typical experience, it was anticipated that a higher amount of closantel would have a favourable effect on the blood plasma levels. Increasing the closantel concentration in such formulations was readily achieved, allowing higher dosing of closantel in the combination product. Despite these attempts at higher dosing, administration of closantel at 5 mg/kg did not increase blood plasma levels at all and even at the exceptionally high dosing level of 7.5 mg/kg the blood plasma levels only increased to 31 ppm (Examples 3 and 4 in Table 1). Therefore the proposed formulations available from following the teachings of the reference WO 95/05812 surprisingly failed to deliver the expected solution to the problem of obtaining a satisfactory combination product.

Objects of the Invention

Accordingly, it is an object of the present invention to provide improved veterinary pharmaceutical preparations. In particular it is an object of the invention to provide a composition having activity against a broad range of endo- and ectoparasites including flukes. It is a further object of this invention to provide preparations which are suitable for administration by injection. A still further object of the invention is to provide a veterinary pharmaceutical product combining

ivermectin and closantel in an effective formulation enabling enhanced bioavailability of closantel in excess of the observed prior art levels.

Summary of the Invention

Surprisingly it has been found that the inclusion of a significant amount of a polymeric moiety, especially polyvinylpyrrolidone (PVP) has a dramatic effect on the bioavailability of salicylanilides such as closantel in parasiticial formulations. Lutrol, (a polyoxypropylene/polyoxyethylene block copolymer, known as a polymeric surfactant) also showed some benefit in this respect but not as demonstrably effective as the PVP.

Accordingly, the invention enables the provision of injectable parasiticial compositions, especially combination products, based on for example an avermectin or milbemycin together with another parasiticial agent of the salicylanilide type with effective bioavailability of the parasiticial agents.

Thus according to one aspect of the invention, a parasiticial composition comprises a first parasiticial agent selected from amongst the avermectins and the milbemycins, together with another parasiticial agent selected from the salicylanilides, in a physiologically tolerable solvent system rendering the said composition suitable for injection, *characterised in that* the composition comprises an amount of a polymeric species that is effective to provide blood plasma levels of the salicylanilide parasiticial agent greater than about 20 ppm, over a period of treatment.

Preferably, the polymeric species is selected from a polyvinylpyrrolidone (PVP) or a polyoxypropylene/polyoxyethylene block copolymer, the former being especially preferred.

Polyvinylpyrrolidone is available in powder form of various molecular weights (M_w circa 10,000 up to 55,000, and above: Aldrich Catalogue 2000-2001) for pharmaceutical use and is generally adopted as a dispersing and suspending agent (Merck Index). Thus it is surprising that it offers the observed beneficial effect for two reasons. Firstly, its normal use is in preparing the formulation, but here it is unnecessary, because the actives are readily introduced to the solvent system without such an aid, indeed our findings in this respect bear out the

findings of the earlier patent applicant (Phoenix – W 01/60380) in terms of making a stable formulation. Secondly, a person experienced in this art would predict that macromolecules may have an adverse effect on bioavailability when present in a preparation due to interaction between the macromolecule and the drug component, leading to the so-called “drug binding” impairing bioavailability.

Therefore, hitherto on the basis of the present state of the art, prior to the present work, it could not have predicted that PVP would have a beneficial effect with respect to inhibiting depletion of effective amounts of closantel from blood after the dose is administered. Thus PVP is surprisingly found to be effective in the manufacture of a parasitocidal composition comprising closantel having long acting efficacy, such that the amount of PVP used enables the desired period of efficacy to be designed into the formulation, to provide a controllable period of effective treatment whilst still permitting slaughter for human consumption of the treated animal if required having regard to the legally prescribed withdrawal period.

A suitable solvent system comprises glycerol formal (GF), or a mixture of propylene glycol (PG) and GF, or a mixture of a polyethylene glycol (PEG) and GF. A range of PEG solvents according to molecular weight is commercially available, and any of those, or others that may yet be made available, may be chosen for convenience provided that the PEG is presented or rendered available as a liquid during formulation. Typically, PEG 200 to 1500 are readily to hand from commercial sources, and thus can be used for the purposes herein, but PEG 200 to PEG 600 are usefully employed in this invention. A preferred solvent system consists of PEG 200 with GF.

Thus according to the invention, it is now possible to obtain in a single injectable formulation, an avermectin, preferably ivermectin, and a salicylanilide, preferably closantel, which is effective to deliver closantel when administered to an animal such that an effective plasma concentration of closantel is readily achieved.

The potential ranges of the preferred parasitocidal agents useful in such formulations are:

Ivermectin - from 0.1 to 10% w/v, preferably 1 to 5 % w/v;
Closantel - from 1 to 30% w/v, preferably 1 to 15 % w/v.

The quantity of polymeric species, especially polyvinylpyrrolidone, required to be effective depends on the desired salicylanilide activity of the mixture but typically at least 11% PVP is required to permit the higher effective amounts of e.g. closantel desired to be achieved, and good results are demonstrated at levels of 15% or more. With regard to relative ratio of polymeric component to closantel, it has been demonstrated that good bioavailability of closantel is achieved when a ratio of greater than 1.44 :1 is established in the formulation.

Modes for Carrying Out the Invention

Formulation Examples-Solvent Systems

10 **A:** In the preparation of a 0.5%w/v ivermectin parenteral solution the composition was as follows:

	Ivermectin	0.5%w/v
	Closantel (as Na salt)	12.5%w/v
	PVP (K12)	18.0%w/v
15	Glycerol Formal	<i>q.s. ad 100%v/v</i>

B: In the preparation of a 0.5%w/v ivermectin parenteral solution the composition was as follows:

	Ivermectin	0.5%w/v
	Closantel (as Na salt)	12.5%w/v
20	PVP (K12)	18.0%w/v
	Propylene Glycol	40%w/v
	Glycerol Formal	<i>q.s. ad 100%v/v</i>

C: In the preparation of a 0.5%w/v ivermectin parenteral solution the composition was as follows:

25	Ivermectin	0.5%w/v
	Closantel (as Na salt)	12.5%w/v
	PVP (K12)	18.0%w/v
	Polyethylene Glycol 200	40%w/v
	Glycerol Formal	<i>q.s. ad 100%v/v</i>

General Method of Formulation:

These formulations were made up following usual industry practice. Thus PVP is initially dissolved in the PEG 200 and half the volume of glycerol formal. Then the closantel is introduced with stirring as required. Finally the ivermectin is added, and dissolved, and the remainder of the solvent is added to the final desired volume. The solution is sterilised by membrane filtration and packaged aseptically.

Test Results:

Performance Examples 1 to 7 describe the trials of prior art proposals in comparison with formulations according to the invention.

Test Example 1:

2.5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal.

Test Example 2:

2.5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal and polyethylene glycol 200.

Test Example 3:

5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal with polyethylene glycol 200.

Test Example 4:

7.5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal with polyethylene glycol 200.

Test Example 5:

5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal, and containing PVP.

Test Example 6:

5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal with propylene glycol, and containing PVP.

Test Example 7:

5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal with polyethylene glycol 200, and containing PVP.

The results of bioavailability with respect to closantel are presented in the Table 1 hereinafter.

Table 1

Example	Solvent System	Ivermectin Content (%w/v)	Closantel Content (%w/v)	PVP Content (%w/v)	Closantel Dose (mg/kg)	Closantel Maximum Plasma level (ppm)
1	GF	0.5	6.25	-	2.5	14.8
2	PEG/GF	0.5	6.25	-	2.5	19.3
3	PEG/GF	0.5	25	-	5	18.6
4	PEG/GF	0.5	18.75	-	7.5	31.3
5	GF	0.5	12.5	18	5	52.8
6	PG/GF	0.5	12.5	18	5	48.3
7	PEG/GF	0.5	12.5	18	5	57.8

GF = Glycerol Formal

PEG = Polyethylene Glycol

PG = Propylene Glycol

In formulations using two solvents the first mentioned solvent is added at 40%

With the second added to make up the required volume.

Industrial Applicability

10 In view of the aforesaid advantages and properties of the compositions described herein, the invention will be usefully applied in the field of veterinary medicine in particular for combating endoparasites and ectoparasites typically afflicting livestock such as bovines, equines, ovines and caprines.

CLAIMS

1. An anti-parasitic composition containing an effective amount of a salicylanilide anti-parasitic compound together with a sufficient amount of a polymeric species moiety that is effective to provide blood plasma levels of the said compound greater than about 20 ppm over a period of treatment, and an effective amount of at least one other anti-parasitic compound, in a physiologically acceptable solvent.
2. A composition as claimed in claim 1, wherein the polymeric species is selected from the group consisting of polyvinylpyrrolidones (PVP).
3. A composition as claimed in claim 1, wherein the polymeric species is selected from the group consisting of polyoxypropylene/polyoxyethylene block copolymers.
4. A composition according to any one of claims 1 to 3, wherein the salicylanilide is closantel.
5. A composition according to any one of claims 1 to 3, wherein the other anti-parasitic compound is selected from the group consisting of avermectins.
6. A composition according to any one of claims 1 to 3, wherein the other anti-parasitic compound is selected from the group consisting of milbemycins.
7. A composition according to claim 4, wherein the other anti-parasitic compound is ivermectin present in an amount in the range 0.1 to 10% (w/v).
8. A composition according to claim 4, wherein closantel is present in an amount of 1 to 30% (w/v).
9. A composition according to any one of claims 1 to 3, wherein the solvent is selected from the group consisting of propylene glycol (PG), polyethylene glycols (PEG), glycerol formal, and water individually or in combination.
10. A composition according to any one of claims 1 to 3, wherein the polymeric species is present in an amount in the range of from 1% to 35% and above.

11. A composition according to claim 4, wherein the polymeric species is PVP present in an amount of at least 11%.
 12. A composition according to any one of the Formulation Examples or Test Examples 5, 6, or 7 hereinbefore.
-

AMENDED CLAIMS

[received by the International Bureau on 15 July 2003 (15.07.03);
original claim 1 amended; claims 2-12 unchanged (3 pages)]

1. An anti-parasitic composition containing an effective amount of a salicylanilide anti-parasitic compound together with a sufficient amount of a vinyl polymeric species moiety that is effective to provide blood plasma levels of the said compound greater than about 20 ppm over a period of treatment, and an effective amount of at least one other anti-parasitic compound, in a physiologically acceptable solvent.
2. A composition as claimed in claim 1, wherein the polymeric species is selected from the group consisting of polyvinylpyrrolidones (PVP).
3. A composition as claimed in claim 1, wherein the polymeric species is selected from the group consisting of polyoxypropylene/polyoxyethylene block copolymers.
4. A composition according to any one of claims 1 to 3, wherein the salicylanilide is closantel.
5. A composition according to any one of claims 1 to 3, wherein the other anti-parasitic compound is selected from the group consisting of avermectins.
6. A composition according to any one of claims 1 to 3, wherein the other anti-parasitic compound is selected from the group consisting of milbemycins.
7. A composition according to claim 4, wherein the other anti-parasitic compound is ivermectin present in an amount in the range 0.1 to 10% (w/v).
8. A composition according to claim 4, wherein closantel is present in an amount of 1 to 30% (w/v).
9. A composition according to any one of claims 1 to 3, wherein the solvent is selected from the group consisting of propylene glycol (PG),

polyethylene glycols (PEG), glycerol formal, and water individually or in combination.

10. A composition according to any one of claims 1 to 3, wherein the polymeric species is present in an amount in the range of from 1% to 35% and above.

11. A composition according to claim 4, wherein the polymeric species is PVP present in an amount of at least 11%.
12. A composition according to any one of the Formulation Examples or Test Examples 5, 6, or 7 hereinbefore.

Statement under Article 19(1)

The references WO 95/05812, WO 95/16447, WO 02/09764 and WO 02/094221 do not provide formulations which comprise an amount of vinyl polymeric species which has been shown by the applicant to be effective in providing formulations that can enhance the levels of closantel in the plasma to in excess of what would be expected based on the dose rate. Accordingly, Claim 1 has been amended to restrict the claim to "vinyl polymeric species" whilst all the other claims (Claims 2 to 12) remain unchanged.

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/GB 03/00645

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/7048 A61K31/277 A61K47/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 16447 A (BURKE MICHAEL HILARY) 22 June 1995 (1995-06-22) example 1	1,2,9,10
X	WO 95 05812 A (HARVEY COLIN MANSON ;ASHMONT HOLDINGS LTD (NZ)) 2 March 1995 (1995-03-02) cited in the application example 4 claims 1-8	1,4-11
X	WO 02 09764 A (BYRON BASSETT LTD ;RAZZAK MAJID HAMEED ABDUL (NZ); TUCKER IAN GEOR) 7 February 2002 (2002-02-07) claims 1,5-8; example 2	1,4-11
	-/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

11 June 2003

Date of mailing of the international search report

24/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Young, A

INTERNATIONAL SEARCH REPORT

Internati Application No

PCT/GB 03/00645

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 128 632 A (LO PAK-KAN A ET AL) 5 December 1978 (1978-12-05) example 2 abstract	1,2,9-11
A	FR 2 739 778 A (VIRBAC LAB) 18 April 1997 (1997-04-18) claims 1-7	1,4-11
A	US 6 193 989 B1 (LAMBERTI JORGE CARLOS) 27 February 2001 (2001-02-27) example 1 abstract	1,2,5,7, 9-11
A	EP 0 628 302 A (COLGATE PALMOLIVE CO) 14 December 1994 (1994-12-14) example 1 claims 1,2,7	1-12
X,P	WO 02 094221 A (BIFFIN JOHN RAYMOND ;REGTOP HUBERTUS LEONARDUS (AU); WAYNE MILES D) 28 November 2002 (2002-11-28) claims 1,13,48,59,60	1,2,4

INTERNATIONAL SEARCH REPORT

In relation on patent family members

Internati Application No
PCT/GB 03/00645

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9516447	A	22-06-1995	WO 9516447 A1 AU 698431 B2 AU 1216095 A EP 0734258 A1	22-06-1995 29-10-1998 03-07-1995 02-10-1996
WO 9505812	A	02-03-1995	NZ 248486 A AU 695582 B2 AU 7469494 A EP 0724437 A1 WO 9505812 A1 ZA 9406195 A	26-07-1996 13-08-1998 21-03-1995 07-08-1996 02-03-1995 22-05-1995
WO 0209764	A	07-02-2002	AU 8030601 A WO 0209764 A1	13-02-2002 07-02-2002
US 4128632	A	05-12-1978	AR 221862 A1 AT 363600 B AT 106679 A AU 522422 B2 AU 4391479 A DE 2962602 D1 DK 57479 A EP 0003682 A1 HU 177873 B IE 47833 B1 IT 1113720 B JP 54117019 A NZ 189536 A OA 6239 A PH 13191 A PL 213352 A1 YU 25679 A1 ZA 7900597 A ZW 3579 A1	31-03-1981 10-08-1981 15-01-1981 03-06-1982 23-08-1979 09-06-1982 14-08-1979 22-08-1979 28-01-1982 27-06-1984 20-01-1986 11-09-1979 11-02-1981 30-06-1981 16-01-1980 03-12-1979 29-02-1984 29-10-1980 10-09-1980
FR 2739778	A	18-04-1997	FR 2739778 A1 AU 7304196 A EP 0859609 A1 WO 9713508 A1	18-04-1997 30-04-1997 26-08-1998 17-04-1997
US 6193989	B1	27-02-2001	AT 212849 T AU 726556 B2 AU 5936798 A BR 9705242 A DE 69803710 D1 DE 69803710 T2 EP 0867186 A1 ES 2173545 T3 NZ 330005 A US 6054140 A ZA 9801925 A	15-02-2002 09-11-2000 24-09-1998 19-12-2000 21-03-2002 21-11-2002 30-09-1998 16-10-2002 29-06-1999 25-04-2000 23-10-1998
EP 0628302	A	14-12-1994	US 5275805 A AU 6321394 A CA 2125542 A1 EP 0628302 A2 JP 7048238 A PH 30185 A	04-01-1994 15-12-1994 12-12-1994 14-12-1994 21-02-1995 21-01-1997

INTERNATIONAL SEARCH REPORT

In relation on patent family members

Internatl Application No

PCT/GB 03/00645 .

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0628302	A	ZA 9403836 A	01-12-1995
WO 02094221	A	28-11-2002	WO 02094221 A1
		AU 2925502 A	28-11-2002
			21-11-2002

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)